122 related articles for article (PubMed ID: 7650125)
1. Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome in an in-vitro fertilization programme.
Ng E; Leader A; Claman P; Domingo M; Spence JE
Hum Reprod; 1995 Apr; 10(4):807-10. PubMed ID: 7650125
[TBL] [Abstract][Full Text] [Related]
2. Decreased incidence of severe ovarian hyperstimulation syndrome in high risk in-vitro fertilization patients receiving intravenous albumin: a prospective study.
Shalev E; Giladi Y; Matilsky M; Ben-Ami M
Hum Reprod; 1995 Jun; 10(6):1373-6. PubMed ID: 7593499
[TBL] [Abstract][Full Text] [Related]
3. Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study.
Bellver J; Muñoz EA; Ballesteros A; Soares SR; Bosch E; Simón C; Pellicer A; Remohí J
Hum Reprod; 2003 Nov; 18(11):2283-8. PubMed ID: 14585874
[TBL] [Abstract][Full Text] [Related]
4. Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an in vitro fertilization program: a prospective, randomized, placebo-controlled study.
Shoham Z; Weissman A; Barash A; Borenstein R; Schachter M; Insler V
Fertil Steril; 1994 Jul; 62(1):137-42. PubMed ID: 8005278
[TBL] [Abstract][Full Text] [Related]
5. Prophylactic intravenous hydroxyethyle starch solution prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized, double-blind and placebo-controlled study.
König E; Bussen S; Sütterlin M; Steck T
Hum Reprod; 1998 Sep; 13(9):2421-4. PubMed ID: 9806261
[TBL] [Abstract][Full Text] [Related]
6. Intravenous albumin prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized and controlled study.
Isik AZ; Gokmen O; Zeyneloglu HB; Kara S; Keles G; Gulekli B
Eur J Obstet Gynecol Reprod Biol; 1996 Dec; 70(2):179-83. PubMed ID: 9119100
[TBL] [Abstract][Full Text] [Related]
7. Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study.
Gokmen O; Ugur M; Ekin M; Keles G; Turan C; Oral H
Eur J Obstet Gynecol Reprod Biol; 2001 Jun; 96(2):187-92. PubMed ID: 11384805
[TBL] [Abstract][Full Text] [Related]
8. Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome.
Shaker AG; Zosmer A; Dean N; Bekir JS; Jacobs HS; Tan SL
Fertil Steril; 1996 May; 65(5):992-6. PubMed ID: 8612863
[TBL] [Abstract][Full Text] [Related]
9. Severe ovarian hyperstimulation syndrome: is it really preventable by prophylactic intravenous albumin?
Ndukwe G; Thornton S; Fishel S; Dowell K; Aloum M
Fertil Steril; 1997 Nov; 68(5):851-4. PubMed ID: 9389814
[TBL] [Abstract][Full Text] [Related]
10. Use of intramuscular progesterone versus intravenous albumin for the prevention of ovarian hyperstimulation syndrome.
Costabile L; Unfer V; Manna C; Gerli S; Rossetti D; Di Renzo GC
Gynecol Obstet Invest; 2000; 50(3):182-5. PubMed ID: 11014951
[TBL] [Abstract][Full Text] [Related]
11. The optimal length of 'coasting protocol' in women at risk of ovarian hyperstimulation syndrome undergoing in vitro fertilization.
Nardo LG; Cheema P; Gelbaya TA; Horne G; Fitzgerald CT; Pease EH; Brison DR; Lieberman BA
Hum Fertil (Camb); 2006 Sep; 9(3):175-80. PubMed ID: 17008270
[TBL] [Abstract][Full Text] [Related]
12. Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome.
Chen CD; Wu MY; Yang JH; Chen SU; Ho HN; Yang YS
Fertil Steril; 1997 Aug; 68(2):287-91. PubMed ID: 9240258
[TBL] [Abstract][Full Text] [Related]
13. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients.
Humaidan P; Polyzos NP; Alsbjerg B; Erb K; Mikkelsen AL; Elbaek HO; Papanikolaou EG; Andersen CY
Hum Reprod; 2013 Sep; 28(9):2511-21. PubMed ID: 23753114
[TBL] [Abstract][Full Text] [Related]
14. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
[TBL] [Abstract][Full Text] [Related]
15. Reduced incidence of ovarian hyperstimulation syndrome by prophylactic infusion of hydroxyaethyl starch solution in an in-vitro fertilization programme.
Graf MA; Fischer R; Naether OG; Baukloh V; Tafel J; Nückel M
Hum Reprod; 1997 Dec; 12(12):2599-602. PubMed ID: 9455820
[TBL] [Abstract][Full Text] [Related]
16. Embryo freezing for preventing Ovarian Hyperstimulation Syndrome.
D'Angelo A; Amso N
Cochrane Database Syst Rev; 2002; (2):CD002806. PubMed ID: 12076453
[TBL] [Abstract][Full Text] [Related]
17. Human albumin is effective in prevention of severe OHSS.
Al-Inany HG
Acta Obstet Gynecol Scand; 2001 Oct; 80(10):878-82. PubMed ID: 11580730
[TBL] [Abstract][Full Text] [Related]
18. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG.
Seyhan A; Ata B; Polat M; Son WY; Yarali H; Dahan MH
Hum Reprod; 2013 Sep; 28(9):2522-8. PubMed ID: 23633553
[TBL] [Abstract][Full Text] [Related]
19. Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome.
Youssef MA; Al-Inany HG; Evers JL; Aboulghar M
Cochrane Database Syst Rev; 2011 Feb; (2):CD001302. PubMed ID: 21328249
[TBL] [Abstract][Full Text] [Related]
20. The prevention of ovarian hyperstimulation syndrome.
Corbett S; Shmorgun D; Claman P; ;
J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
